Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis

Impact ofEGFRmutations andKRASamino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer

(2016) Stéphane Renaud et al.   Future Oncology

Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases

(2015) Shuimei Luo et al.   Oncotarget

Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure

(2014) Yong Cai et al.   Asian Pacific Journal of Cancer Prevention

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer

(2014) Jingze Zhang et al.   CANCER LETTERS

ADAM9 Promotes Lung Cancer Metastases to Brain by a Plasminogen Activator-Based Pathway

(2014) C.-Y. Lin et al.   CANCER RESEARCH

EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation

(2014) M. Wang et al.   CANCER RESEARCH

Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature

(2014) Giuseppe Lombardi et al.   CANCER TREATMENT REVIEWS

Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis

(2014) Manuel Valiente et al.   CELL

Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer

(2014) Feng Wang et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer

(2014) Ling Cai et al.   JOURNAL OF NEURO-ONCOLOGY

Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases

(2014) Siow Ming Lee et al.   JNCI-Journal of the National Cancer Institute

The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma

(2013) Hongqing Zhuang et al.   INTERNATIONAL JOURNAL OF CANCER

A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320

(2013) Paul W. Sperduto et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives

(2013) Lars Arne Berger et al.   LUNG CANCER

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma

(2013) HongQing Zhuang et al.   Drug Design Development and Therapy

Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study

(2012) Yin-Duo Zeng et al.   Asian Pacific Journal of Cancer Prevention

EGFR mutation status in brain metastases of non-small cell lung carcinoma

(2012) Fanny Burel-Vandenbos et al.   JOURNAL OF NEURO-ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

(2011) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)

(2011) Gianfranco A. Pesce et al.   EUROPEAN JOURNAL OF CANCER

Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases

(2011) Paul W. Sperduto et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor

(2011) Britta Weber et al.   Journal of Thoracic Oncology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Treatment of brain metastases: Review of phase III randomized controlled trials

(2011) Silvia Scoccianti et al.   RADIOTHERAPY AND ONCOLOGY

Whole-Brain Radiation Therapy Plus Concomitant Temozolomide for the Treatment of Brain Metastases From Non–Small-Cell Lung Cancer: A Randomized, Open-Label Phase II Study

(2010) Daniel Chua et al.   Clinical Lung Cancer

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

(2010) R. Porta et al.   EUROPEAN RESPIRATORY JOURNAL

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

(2010) Yosuke Togashi et al.   Journal of Thoracic Oncology

WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis

(2009) Don X. Nguyen et al.   CELL

HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors

(2009) M. Sun et al.   CLINICAL CANCER RESEARCH

Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer

(2009) Lorenzo Daniele et al.   Journal of Thoracic Oncology

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

(2008) C.-H. Gow et al.   ANNALS OF ONCOLOGY